Table 1.

Summary of some of the recently reported PK-PD studies undertaken in children

Drug	Age range	Numberof subjects	Age related change inconcentration response (CR)	Study
Bumetanide	Infants, children, young adults	9	No detected difference in CR with age	Marshall et al. [9]
Cyclosporin	3 months to 39 years	56	Increased CR effect in <1 to 4 age group	Marshall et al. [10]
Lansoprazole	18 days to 14 years	40	Increased antisecretory effect in infants <6 months	Tran et al. [11]
Midazolam	Pre term 29 weeks	31	Decreased CR (sedation response)	de Wildt et al. [12]
Mivacurium	3–6 years, 10–14 years	10, 10	No major differences in PK-PD	Stergaard et al. [13]
Nizatidine	5 days to 50 years	93	Possible greater CR effect in children?	Abdel-Rahman et al. [14]
Ranitidine	4–11 years	29	No major differences in PK-PD	Orenstein et al. [15]
Rocuronium	Infants, children, adult	14, 23, 21	Greater CR effect in infants compared with children	Saldien et al. [16]
Sotolol for SVT	0.03–41 years	81	Increased CR (QTc interval prolongation) in neonates	Laer et al. [17]
Warfarin	1–11 years, 12–18 years, 37–76 years	38, 15, 81	Increased CR effect (INR/dose) in 1–11 age group	Takahashi et al.[18]